Menu

Scientists Successfully Transplant Human Leukemia Cells into Mice

While studying the progression of healthy cells into cancerous ones, researchers discover a way to engraft human blood cells into animals.

Apr 1, 2017
Diana Kwon

TRANSFORMATIONS: An artistic representation of cancer progression in a cell, from normal to a leukemic state (from left to right)LEWIS LONG

EDITOR'S CHOICE IN CANCER BIOLOGY

The paper
A.G. Kotini et al., “Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia,” Cell Stem Cell, 20:315-28.e7, 2017.

Cancer continuum
In recent years, cancer researchers have discovered that myeloid malignancies lie on a continuum of increasing severity, starting as precancerous mutations in blood cell precursors, then progressing to bone marrow disorders, and, finally, developing into acute myeloid leukemia.

Transitions
Eirini Papapetrou of the Icahn School of Medicine at Mount Sinai and colleagues followed disease progression by reprogramming cells from patients with various stages of myeloid malignancies, including premalignant cells, into pluripotent stem cells in their precancerous state. Then, by differentiating them back into blood cells, the team established cell lines representing specific stages of disease. “What we want to do now is understand the exact molecular/cellular events that drive the stepwise progression from normal cells to leukemic cells,” says Papapetrou.

Transplants  
The researchers discovered that when they converted full-blown leukemia cells into stem cells and back into blood, they could transplant them into mice—a feat that had not been accomplished before with human blood cancer. “One of the holy grails of blood stem cell research is the ability to produce transplantable stem cells,” says Stanford University’s Ravindra Majeti, whose group concurrently reported transplantable leukemic cells using a similar approach (Cell Stem Cell, 20:329-44.e7, 2017). “It is one of the big hurdles limiting the translational applications for blood disease.”

Solving the puzzle
“One of the future goals is to figure out what it is that really can drive an engraftable cell,” says Papapetrou’s coauthor, Michael Kharas of Memorial Sloan Kettering Cancer Center. “We think that the leukemia-derived cells were able to maintain or acquire some aspect of the blood stem cell program that was not in the other cell types.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.